Platelet Disorders Gene Sequencing Panel

ABCG5	*ABCG8*	*ACBD5*	*ACTN1*	*ANKRD26*	*ANO6 (TMEM16F)*
AP3B1	*AP3D1*	*ARPC1B*	*BLOC1S3*	*BLOC1S6*	*CD36*
CYCS	*DIAPH1*	*DTNBP1*	*ETV6*	*FERMT3*	*FLI1*
FLNA	*FYB1*	*GATA1*	*GFI1B*	*GP1BA*	*GP1BB*
GP6	*GP9*	*HOXA11*	*HPS1*	*HPS3*	*HPS4*
HPS5	*HPS6*	*ITGA2*	*ITGA2B*	*ITGB3*	*LYST (CHS1)*
MASTL	*MECOM*	*MLPH*	*MPIG6B*	*MPL*	*MYH9*
NBEA	*NBEAL2*	*ORAI1*	*P2RX1*	*P2RY12*	*PLA2G4A*
PRKACG	*RAB27A*	*RASGRP2*	*RBM8A*	*RUNX1*	*SLFN14*
STIM1	*STX11*	*STXBP2*	*TBXA2R*	*TBXAS1*	*THPO*
TUBB1	*UNC13D*	*VIPAS39*	*VPS33B*	*VPS45*	*WAS*

Description:

The Platelet Disorders Gene Sequencing Panel utilizes Whole Exome Sequencing (WES) technology to identify inherited forms of platelet dysfunction. Utilizing a predefined list of 66 clinically significant genes, this panel analyzes mutations related to adhesion and activation receptor genes, secretion and membrane regulation genes, and platelet production genes related to genetically inherited platelet disorders. Compared to WES, this targeted approach results in fewer sequence changes identified: allowing for a shorter turnaround time and decreased cost of testing. This test will be performed on the proband only and will not include the identification of incidental findings.

Indications:

- Platelet dysfunction/defect
- Abnormal bleeding
- Unexplained thrombocytopenia
- Easy bruising/spontaneous ecchymoses
- Positive family history of bleeding disorders or platelet function disorders

What Is Reported?

Variants that will be discussed in detail in the report:

- **Pathogenic/likely pathogenic variants:** Variants that are known to be pathogenic or for which the laboratory has sufficient evidence suggesting pathogenicity.

Variants that will be listed in the report:

- Variants of uncertain clinical significance.

What is not reported?

- Variants in genes not included in the predefined gene list
- Variants where there is currently no evidence of association with the disease and that are identified in healthy individuals (benign or likely benign variants)
- Variants that predict an increased risk of diseases, but do not cause a disease by themselves (risk alleles).

Cincinnati Children's®
changing the outcome together

Laboratory of Genetics and Genomics
CLIA#: 36D0656333
Phone: (513) 636-4474
Fax: (513) 636-4373
Email: LabGeneticCounselors@cchmc.org
www.cincinnatichildrens.org/genetics

Genetic Conditions Commonly Associated with Platelet Disorders

Gene	Inheritance	Condition
ABCG5	AR	Macrothrombocytopenia and sitosterolemia
ABCG8	AR	Macrothrombocytopenia and sitosterolemia
ACBD5	AD	Autosomal Dominant Thrombocytopenias
ACTN1	AD	Congenital Macrothrombocytopenia
ANKRD26	AD	Autosomal Dominant Thrombocytopenias
ANO6 (TMEM16F)	AR	Scott Syndrome
AP3B1	AR	Hermansky-Pudlak syndrome
AP3D1	AR	Hermansky-Pudlak syndrome 10
ARPC1B	AR	Platelet abnormalities with eosinophilia and immune-mediated inflammatory disease
BLOC1S3	AR	Hermansky-Pudlak syndrome
BLOC1S6	AR	Hermansky-Pudlak syndrome
CD36	AR	Platelet glycoprotein IV deficiency
CYCS	AD	Autosomal Dominant Thrombocytopenias
DIAPH1	AD	Macrothrombocytopenia and hearing loss
DTNBP1	AR	Hermansky-Pudlak syndrome
ETV6	AD	Thrombocytopenia and cancer susceptibility
FERMT3	AR	Leukocyte adhesion deficiency, type III
FLI1	AD/AR	Paris-Trousseau (Jacobson) Syndrome, bleeding disorder
FLNA	X linked	X-linked thrombocytopenia with PVNH
FYB1	AR	Thrombocytopenia 3
GATA1	X linked	X-linked thrombocytopenia
GFI1B	AD/AR	Gray platelet syndrome, bleeding disorder
GP1BA	AD/AR	Bernard-Soulier syndrome, Platelet-type von Willebrand's disease
GP1BB	AR	Bernard-Soulier syndrome, giant platelet disorder
GP6	AR	GPVI deficiency
GP9	AR	Bernard-Soulier syndrome
HOXA11	AD	Amegakaryocytic thrombocytopenia radio-ulnar synostosis
HPS1	AR	Hermansky-Pudlak syndrome
HPS3	AR	Hermansky-Pudlak syndrome
HPS4	AR	Hermansky-Pudlak syndrome
HPS5	AR	Hermansky-Pudlak syndrome
HPS6	AR	Hermansky-Pudlak syndrome
ITGA2	AD	Glycoprotein Ia deficiency
ITGA2B	AD/AR	Glanzmann's thrombasthenia, bleeding disorder
ITGB3	AD/AR	Glanzmann's thrombasthenia, bleeding disorder

Genetic Conditions Commonly Associated with Platelet Disorders, Continued

Gene	Inheritance	Condition
LYST (CHS1)	AR	Chediak-Higashi syndrome
MASTL	AD	Autosomal Dominant Thrombocytopenias
MECOM	AD	Radioulnar synostosis with amegakaryocytic thrombocytopenia 2
MLPH	AR	Griscelli syndrome, type 3
MPIG6B	AR	Thrombocytopenia, anemia, and myelofibrosis
MPL	AD/AR	Congenital amegakaryocytic thrombocytopenia
MYH9	AD	MYH9 Disorders
NBEA	AD	Autism and dense granule deficiency
NBEAL2	AR	Gray platelet syndrome
ORAI1	AD/AR	Stormorken Syndrome
P2RX1	n/a	ADP receptor defects
P2RY12	AR	ADP receptor defects, bleeding disorder
PLA2G4A	AR	Cytosolic phospholipase A2, Deficiency of phospholipase A2 group IVA
PRKACG	AR	Congenital Macrothrombocytopenia
RAB27A	AR	Griscelli syndrome, type 2
RASGRP2	AR	Impaired RAP1 activation and $\alpha_{IIb}\beta_3$ signaling, bleeding disorder
RBM8A	AR	Thrombocytopenia absent radius (TAR) syndrome
RUNX1	AD	Thrombocytopenia and AML susceptibility
SLFN14	AD	Bleeding disorder, platelet-type, 20
STIM1	AD/AR	Stormorken Syndrome
STX11	AR	Familial HLH types 4
STXBP2	AR	Familial HLH types 5
TBXA2R	AD	Thromboxane A2 receptor deficiency
TBXAS1	AD/AR	Thromboxane A synthase (Ghosal syndrome), Thromboxane Synthase deficiency
THPO	AD	Cyclic Thromboctyopenia
TUBB1	AD	Congenital Macrothrombocytopenia
UNC13D	AR	Familial HLH types 3
VIPAS39	AR	ARC Syndrome, Arthrogryposis-renal dysfunction-cholestasis syndrome
VPS33B	AR	Arthrogryposis-renal dysfunction-cholestasis syndrome
VPS45	AR	Congenital neutropenia & platelet α granule defect
WAS	X linked	Wiskott-Aldrich syndrome

Methodology:

Procedure: The Platelet Disorders Gene Sequencing Panel uses the Agilent SureSelect CRE V1 kit to capture the exonic regions of genes from the genomic DNA extracted from the patient. Targeted regions are sequenced using the Illumina HiSeq 2500 sequencing system with 125 base pair (bp) paired-end reads. Sequence reads are mapped and compared to human genome build UCSC hg19. Variants within exons and flanking sequences of +/- 20bps are identified and evaluated by a validated in-house developed bioinformatics analysis pipeline that includes the usage of GATK 4.0 and Alamut Batch 1.4.4 software packages. Mutations in the promoter region of *ANKRD26* are analyzed; allele specific analysis for the 253kb inversion as well as targeted analysis of the c.118-308 region in *UNC13D* are performed. Data quality is assessed to confirm it has a minimum coverage of 20X for >95% of targets of interest.

Technical Limitations:

- Pathogenic variants may be present in a portion of the genes not covered by this test and therefore would not be identified. Thus, the absence of reportable findings for any gene does not mean there are no pathogenic variants.
- Certain types of mutations are not detected. Only single base pair changes or small insertions or deletions of DNA are detected. Large deletions, duplications, or rearrangements, mitochondrial genome mutations, trinucleotide repeat expansions, genes with pseudogenes, mutations in tri-allelic inheritance, and many epigenetic defects may not be detected by this test.

Note: Targeted deletion and duplication analysis of every gene on this panel except *ACBD5, ACTN1, ANKRD26, ANO6, AP3D1, ARPC1B, CD36, CYCS, DIAPH1, ETV6, FERMT3, FLI1, FYB1, GFI1B, GP6, HOXA11, ITGA2, MASTL, MECOM, MPIG6B, NBEA, NBEAL2, P2RX1, P2RY12, PLA2G4A, PRKACG, RUNX1, SLFN14, TBXA2R, TBXAS1, THPO, TUBB1, VIPAS39* and *VPS33B* is clinically available at an additional charge.

Turn-Around Time:

56 days (8 weeks).

Specimen:

At least 3 mls whole blood in a lavender top (EDTA) tube. Label the tube with the patient's name, birth date, and date of collection. Alternatively, 10 mcg of DNA may be submitted.

CPT Codes:

- **Platelet Disorders Gene Sequencing Panel:** 81443
- **Deletion and duplication analysis of any single Gene on the Platelet Disorders Gene Sequencing Panel except *GP1BB* and *WAS*:** 81479
- **Deletion and duplication analysis of *GP1BB*:** 81404
- **Deletion and duplication analysis of *WAS*:** 81406

Shipping Instructions:

Please enclose **test requisition** with sample.
All information must be completed before sample can be processed.

Place samples in styrofoam mailer and ship at room temperature by overnight Federal Express to arrive Monday through Saturday.

Ship to:

Cytogenetics and Molecular Genetics Laboratories
3333 Burnet Avenue NRB 1042
Cincinnati, OH 45229
513-636-4474

References:

Bolton-Maggs, P.H.B., E.A. Chalmers, et al. (2006) A Review of Inherited Platelet Disorders with Guidelines for Their Management on Behalf of the UKHCDO. British Journal of Haematology 135(5): 603–33.

Dixon-Salazar TJ, Silhavy JL, et al. (2012) Exome sequencing can improve diagnosis and alter patient management. Sci Transl Med. 4(138):138ra78. Handin, R.I. (2005) Inherited Platelet Disorders. Hematology. American Society of Hematology. Education Program: 396–402.

Freson, K. and Turro, E. (2017) High-throughput sequencing approaches for diagnosing hereditary bleeding and platelet disorders. Journal of Thrombosis and Haemostasis 15(7): 1262–72.

Nurden, A.T. and P. Nurden (2014) Congenital Platelet Disorders and Understanding of Platelet Function. British Journal of Haematology 165(2): 165–78.

Romasko, E.J., B. Devkota, et al. (2018) Utility and Limitations of Exome Sequencing in the Molecular Diagnosis of Pediatric Inherited Platelet Disorders. American Journal of Hematology 93(1):8-16.